AUS
NZ
UK
CA
USA
IND
Highlights:
- VOQUEZNA® shows rapid relief for heartburn in Non-Erosive GERD.
- ACG Outstanding Research Award recognizes significant findings from the PHALCON-NERD-201 trial.
- On-demand dosing could revolutionize treatment options for patients with episodic heartburn.
Phathom Pharmaceuticals, Inc. (Nasdaq:PHAT) is making waves in the biopharmaceutical industry with its groundbreaking treatment, VOQUEZNA® (vonoprazan). This first-in-class potassium-competitive acid blocker (PCAB) has already received FDA approval for various gastrointestinal conditions, including heartburn relief for Non-Erosive Gastroesophageal Reflux Disease (GERD) and treatment for Erosive Esophagitis. Now, the company is set to present new data at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, underscoring the potential of VOQUEZNA as an innovative treatment option.
The PHALCON-NERD-201 trial, led by Dr. Ronnie Fass, a prominent gastroenterology expert, focused on the efficacy of "As Needed" dosing of VOQUEZNA for patients with Non-Erosive GERD. This post-hoc analysis revealed compelling evidence supporting VOQUEZNA’s rapid onset of action for episodic heartburn relief. Patients in the study experienced significant improvements in heartburn-free days after switching from daily dosing to an on-demand approach, highlighting the treatment's practicality and effectiveness.
One of the standout findings from the trial is the remarkable speed at which VOQUEZNA alleviates heartburn symptoms. Patients reported relief within an hour of taking the medication, with over 90% experiencing improvement within two hours. This rapid response is particularly crucial for individuals dealing with sudden episodes of heartburn, which can greatly impact quality of life.
Dr. Fass expressed enthusiasm about the trial's outcomes, noting that the low frequency of heartburn after discontinuing daily treatment, combined with the quick relief provided by on-demand dosing, presents a viable alternative for many patients. The ACG's recognition of this research with the Outstanding Research Award in the 'Esophagus' category further cements the significance of these findings within the gastroenterology community.
The double-blind, placebo-controlled study involved 207 patients who underwent a four-week run-in period on a daily VOQUEZNA regimen before transitioning to the on-demand treatment. Notably, heartburn-free days surged from a mere 16.1% at screening to an impressive 82.9% during the daily treatment phase. This substantial increase in symptom-free days underscores the efficacy of VOQUEZNA and its potential to transform the management of GERD.
Looking ahead, Phathom Pharmaceuticals aims to expand upon these findings through larger studies that investigate the long-term benefits and viability of on-demand dosing for patients with Non-Erosive GERD. The implications for both clinical practice and patient quality of life are significant, as more flexible treatment options may lead to better adherence and satisfaction.
